Skip to content
2000
Volume 11, Issue 1
  • ISSN: 2405-4615
  • E-ISSN: 2405-4623

Abstract

The use of nano vesicular carriers has captured widespread attention from researchers across different disciplines. These nanovesicles are readily available, biocompatible, versatile, and stable, making them an appealing area of study. This review delves into an analysis of various trending nanovesicles such as aquasome, bilosome, cerosome, cubosome, enzymosome, ethosome, exosome, glycerosome, herbosome, hexosome, hyalurosome, invasome, liposome, marinosome, niosome, novasome, pharmacosome, phytosome, polymerosome, proniosome, sphingosome, spongosome, terpesome, ufasome, and virosome, and explores their applications in pharmaceuticals, cosmeceuticals, and other industries. Additionally, it discusses patents, clinical trials, advantages and disadvantages of different nanovesicles, shedding light on how different ingredients affect the physicochemical characteristics of these nanovesicles. The review also emphasizes the manifold implications of nanovesicles, particularly in the context of chemotherapy and specific drug targeting.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnm/10.2174/0124054615325001240809093127
2024-08-19
2026-02-27

  • From This Site

    /content/journals/cnm/10.2174/0124054615325001240809093127
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KhopadeA.J. KhopadeS. JainN.K. Development of hemoglobin aquasomes from spherical hydroxyapatite cores precipitated in the presence of half-generation poly(amidoamine) dendrimer.Int. J. Pharm.2002241114515410.1016/S0378‑5173(02)00235‑1 12086730
     [Google Scholar]
  2. JagdaleS. KarekarS. Bird’s eye view on aquasome: Formulation and application.J. Drug Deliv. Sci. Technol.20205810177610.1016/j.jddst.2020.101776
     [Google Scholar]
  3. BhairyS. PitchikaS. MauryaS. PatilJ. Stability and in-vivo efficacy of bile salts containing nanovesicles (bilosomes) for oral delivery of vaccines and poorly soluble active drug molecules.Indo Am J Pharm Res2020101013261344
     [Google Scholar]
  4. BhargavaM. Development and characterization of oral combination vaccine against hepatitis B & influenza.Int. J. Infect. Dis.2023130S139S14010.1016/j.ijid.2023.04.343
     [Google Scholar]
  5. El TaweelM.M. Aboul-EinienM.H. KassemM.A. ElkasabgyN.A. Intranasal zolmitriptan-loaded bilosomes with extended nasal mucociliary transit time for direct nose to brain delivery.Pharmaceutics20211311182810.3390/pharmaceutics13111828 34834242
     [Google Scholar]
  6. ElsheikhM.A. El-FekyY.A. Al-SawahliM.M. AliM.E. FayezA.M. AbbasH. A brain-targeted approach to ameliorate memory disorders in a sporadic Alzheimer’s disease mouse model via intranasal luteolin-loaded nanobilosomes.Pharmaceutics202214357610.3390/pharmaceutics14030576 35335952
     [Google Scholar]
  7. ZafarA. AlruwailiN.K. ImamS.S. Bioactive Apigenin loaded oral nano bilosomes: Formulation optimization to preclinical assessment.Saudi Pharm. J.202129326927910.1016/j.jsps.2021.02.003 33981176
     [Google Scholar]
  8. BinsuwaidanR. SultanA.A. NegmW.A. Bilosomes as nanoplatform for oral delivery and modulated in vivo antimicrobial activity of lycopene.Pharmaceuticals (Basel)2022159104310.3390/ph15091043 36145264
     [Google Scholar]
  9. AbdelgawadR. NasrM. MoftahN.H. HamzaM.Y. Phospholipid membrane tubulation using ceramide doping “Cerosomes”: Characterization and clinical application in psoriasis treatment.Eur. J. Pharm. Sci.201710125826810.1016/j.ejps.2017.02.030 28232140
     [Google Scholar]
  10. YangX. TangY. WangM. Co-delivery of methotrexate and nicotinamide by cerosomes for topical psoriasis treatment with enhanced efficacy.Int. J. Pharm.202160512082610.1016/j.ijpharm.2021.120826 34171426
     [Google Scholar]
  11. TodkeP. ShahV.H. Psoriasis: Implication to disease and therapeutic strategies, with an emphasis on drug delivery approaches.Int. J. Dermatol.201857111387140210.1111/ijd.14047 29923192
     [Google Scholar]
  12. AzmiI.D.M. MoghimiS.M. YaghmurA. Cubosomes and hexosomes as versatile platforms for drug delivery.Ther. Deliv.20156121347136410.4155/tde.15.81 26652281
     [Google Scholar]
  13. EldeebA.E. SalahS. GhorabM. Formulation and evaluation of cubosomes drug delivery system for treatment of glaucoma: Ex-vivo permeation and in-vivo pharmacodynamic study.J. Drug Deliv. Sci. Technol.20195223624710.1016/j.jddst.2019.04.036
     [Google Scholar]
  14. GaballaS.A. El GarhyO.H. AbdelkaderH. Cubosomes: Composition, preparation, and drug delivery applications.J Adv Biomedical Pharm Sci20203119
     [Google Scholar]
  15. HuangJ. PengT. LiY. Ocular cubosome drug delivery system for timolol maleate: Preparation, characterization, cytotoxicity, ex vivo, and in vivo evaluation.AAPS PharmSciTech20171882919292610.1208/s12249‑017‑0763‑8 28429294
     [Google Scholar]
  16. BhosaleR.R. OsmaniR.A. HarkareB.R. GhodakeP.P. Cubosomes: The inimitable nanoparticulate drug carriers.Sch Academic J Pharm201326481486
     [Google Scholar]
  17. ShefrinS. SreelaxmiC.S. VijayanV. NairS.C. Enzymosomes: A rising effectual tool for targeted drug delivery system.Int J Appl Pharmaceut2017961910.22159/ijap.2017v9i6.22556
     [Google Scholar]
  18. EugéniaM. CruzM. GasparM.M. BárbaraM. MartinsF. CorvoM.L. Liposomal superoxide dismutases and their use in the treatment of experimental arthritis.Methods Enzymol.200539139541310.1016/S0076‑6879(05)91022‑7
     [Google Scholar]
  19. GasparM.M. MartinsM.B. CorvoM.L. CruzM.E.M. Design and characterization of enzymosomes with surface-exposed superoxide dismutase.Biochim. Biophys. Acta20031609221121710.1016/S0005‑2736(02)00702‑2
     [Google Scholar]
  20. CorvoM.L. MarinhoH.S. MarcelinoP. Superoxide dismutase enzymosomes: Carrier capacity optimization, in vivo behaviour and therapeutic activity.Pharm. Res.20153219110210.1007/s11095‑014‑1447‑7 25037861
     [Google Scholar]
  21. GasparM.M. BoermanO.C. LavermanP. CorvoM.L. StormG. CruzM.E.M. Enzymosomes with surface-exposed superoxide dismutase: In vivo behaviour and therapeutic activity in a model of adjuvant arthritis.J. Control. Release2007117218619510.1016/j.jconrel.2006.10.018 17169460
     [Google Scholar]
  22. AljohaniA.A. AlanaziM.A. MunahhiL.A. Binary ethosomes for the enhanced topical delivery and antifungal efficacy of ketoconazole.OpenNano20231110014510.1016/j.onano.2023.100145
     [Google Scholar]
  23. ApolinárioA.C. HauschkeL. NunesJ.R. LourençoF.R. LopesL.B. Design of multifunctional ethosomes for topical fenretinide delivery and breast cancer chemoprevention.Colloids Surf. A Physicochem. Eng. Asp.202162312674510.1016/j.colsurfa.2021.126745
     [Google Scholar]
  24. PandeyV. GolhaniD. ShuklaR. Ethosomes: Versatile vesicular carriers for efficient transdermal delivery of therapeutic agents.Drug Deliv.2015228988100210.3109/10717544.2014.889777 24580572
     [Google Scholar]
  25. HaneyM.J. KlyachkoN.L. ZhaoY. Exosomes as drug delivery vehicles for Parkinson’s disease therapy.J. Control. Release2015207183010.1016/j.jconrel.2015.03.033 25836593
     [Google Scholar]
  26. RaguramanR. BhavsarD. KimD. Tumor-targeted exosomes for delivery of anticancer drugs.Cancer Lett.202355821609310.1016/j.canlet.2023.216093 36822543
     [Google Scholar]
  27. SaariH Lázaro-IbáñezE ViitalaT Vuorimaa-LaukkanenE SiljanderP YliperttulaM. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells..J Control Release2015220Pt B7273710.1016/j.jconrel.2015.09.031 26390807
     [Google Scholar]
  28. AbouSamraM.M. FaroukF. AbdelhamedF.M. EmamK.A.F. AbdeltawabN.F. SalamaA.H. Synergistic approach for acne vulgaris treatment using glycerosomes loaded with lincomycin and lauric acid: Formulation, in silico, in vitro, LC-MS/MS skin deposition assay and in vivo evaluation.Int. J. Pharm.202364612348710.1016/j.ijpharm.2023.123487 37805147
     [Google Scholar]
  29. AlamM.S. SultanaN. RashidM.A. Quality by design-optimized glycerosome-enabled nanosunscreen gel of rutin hydrate.Gels20239975210.3390/gels9090752 37754433
     [Google Scholar]
  30. JhaA. Glycerosomes: A new tool for effective drug delivery. Systems of Nanovesicular Drug Delivery.AmsterdamElsevier202210.1016/B978‑0‑323‑91864‑0.00010‑3
     [Google Scholar]
  31. JoshiG. TiwariA. UpadhyayP. Development and characterization of herbosomes complex.J. Pharm. Res.20201006736745
     [Google Scholar]
  32. DewanN. DasguptaD. PanditS. AhmedP. Review on-Herbosomes, A new arena for drug delivery.J. Pharmacogn. Phytochem.201654104
     [Google Scholar]
  33. VoraA. LondheV. PanditaN. Herbosomes enhance the in vivo antioxidant activity and bioavailability of punicalagins from standardized pomegranate extract.J. Funct. Foods20151254054810.1016/j.jff.2014.12.017
     [Google Scholar]
  34. Ubong-IsaacA.U. QueensleyE.A. EnomfonA.J. Herbosomes in the delivery of phytotherapeutics and nutraceuticals: Concepts, applications and future perspective.Covenant J. Phys. Life Sci.2015321022
     [Google Scholar]
  35. JainP.K. KharyaM. GajbhiyeA. Pharmacological evaluation of mangiferin herbosomes for antioxidant and hepatoprotection potential against ethanol induced hepatic damage.Drug Dev. Ind. Pharm.201339111840185010.3109/03639045.2012.738685 23167243
     [Google Scholar]
  36. DuJ.D. LiuQ. SalentinigS. NguyenT.H. BoydB.J. A novel approach to enhance the mucoadhesion of lipid drug nanocarriers for improved drug delivery to the buccal mucosa.Int. J. Pharm.20144711-235836510.1016/j.ijpharm.2014.05.044 24879939
     [Google Scholar]
  37. Gazga-UriosteC. Rivera-BecerrilE. Pérez-HernándezG. Angélica Noguez-MéndezN. Faustino-VegaA. Tomás Quirino-BarredaC. Physicochemical characterization and thermal behavior of hexosomes containing ketoconazole as potential topical antifungal delivery system.Drug Dev. Ind. Pharm.201945116817610.1080/03639045.2018.1526188 30231655
     [Google Scholar]
  38. SwarnakarN.K. JainV. DubeyV. MishraD. JainN.K. Enhanced oromucosal delivery of progesterone via hexosomes.Pharm. Res.200724122223223010.1007/s11095‑007‑9409‑y 17828445
     [Google Scholar]
  39. TanC. HosseiniS.F. JafariS.M. Cubosomes and hexosomes as novel nanocarriers for bioactive compounds.J. Agric. Food Chem.20227051423143710.1021/acs.jafc.1c06747 35089018
     [Google Scholar]
  40. ZoabiA. TouitouE. MargulisK. Recent advances in nanomaterials for dermal and transdermal applications.Colloids and Interfaces2021511810.3390/colloids5010018
     [Google Scholar]
  41. AbruzzoA. CappadoneC. FarruggiaG. LuppiB. BigucciF. CerchiaraT. Glycyrrhetinic acid liposomes and hyalurosomes on Spanish broom, flax, and hemp dressings to heal skin wounds.Molecules20202511255810.3390/molecules25112558 32486398
     [Google Scholar]
  42. AbruzzoA. GiordaniB. ParolinC. Lactobacillus crispatus BC1 biosurfactant delivered by hyalurosomes: An advanced strategy to counteract Candida biofilm.Antibiotics (Basel)20211013310.3390/antibiotics10010033 33401413
     [Google Scholar]
  43. CastangiaI. MancaM.L. Catalán-LatorreA. MaccioniA.M. FaddaA.M. ManconiM. Phycocyanin-encapsulating hyalurosomes as carrier for skin delivery and protection from oxidative stress damage.J. Mater. Sci. Mater. Med.20162747510.1007/s10856‑016‑5687‑4 26886823
     [Google Scholar]
  44. ElhalmoushyP.M. ElsheikhM.A. MatarN.A. Novel berberine-loaded hyalurosomes as a promising nanodermatological treatment for vitiligo: Biochemical, biological and gene expression studies.Int. J. Pharm.202261512152310.1016/j.ijpharm.2022.121523 35104596
     [Google Scholar]
  45. ElsheikhM.A. GaafarP.M.E. KhattabM.A. A HelwahM.K. NoureldinM.H. AbbasH. Dual-effects of caffeinated hyalurosomes as a nano-cosmeceutical gel counteracting UV-induced skin ageing.Int. J. Pharm. X2023510017010.1016/j.ijpx.2023.100170 36844895
     [Google Scholar]
  46. GuoC. YinJ. ChenD. Co-encapsulation of curcumin and resveratrol into novel nutraceutical hyalurosomes nano-food delivery system based on oligo-hyaluronic acid-curcumin polymer.Carbohydr. Polym.20181811033103710.1016/j.carbpol.2017.11.046 29253929
     [Google Scholar]
  47. MancaM.L. CastangiaI. ZaruM. Development of curcumin loaded sodium hyaluronate immobilized vesicles (hyalurosomes) and their potential on skin inflammation and wound restoring.Biomaterials20157110010910.1016/j.biomaterials.2015.08.034 26321058
     [Google Scholar]
  48. MancaM.L. FerraroM. PaceE. Loading of beclomethasone in liposomes and hyalurosomes improved with mucin as effective approach to counteract the oxidative stress generated by cigarette smoke extract.Nanomaterials (Basel)202111485010.3390/nano11040850 33810420
     [Google Scholar]
  49. ScoglioS. BenedettiY. BenvenutiF. BattistelliS. CanestrariF. BenedettiS. Selective monoamine oxidase B inhibition by an Aphanizomenon flos-aquae extract and by its constitutive active principles phycocyanin and mycosporine-like amino acids.Phytomedicine201421799299710.1016/j.phymed.2014.03.006 24690316
     [Google Scholar]
  50. WuS. ZengQ. ZhangZ. Development of sinomenine hydrochloride sustained-release pellet using a novel whirlwind fluidized bed.J. Drug Deliv. Sci. Technol.20227810395610.1016/j.jddst.2022.103956
     [Google Scholar]
  51. XuH. DongL. BinZ. Supramolecular self-assembly of a hybrid ‘hyalurosome’ for targeted photothermal therapy in non-small cell lung cancer.Drug Deliv.202027137838610.1080/10717544.2020.1730521 32098528
     [Google Scholar]
  52. AhmedO.A.A. Badr-EldinS.M. Development of an optimized avanafil-loaded invasomal transdermal film: Ex vivo skin permeation and in vivo evaluation.Int. J. Pharm.201957011865710.1016/j.ijpharm.2019.118657 31491483
     [Google Scholar]
  53. AmmarH.O. TadrosM. SalamN. GhoneimA. Ethosome-derived invasomes as a potential transdermal delivery system for vardenafil hydrochloride: Development, optimization and application of physiologically based pharmacokinetic modeling in adults and geriatrics.Int. J. Nanomedicine2020155671568510.2147/IJN.S261764 32821096
     [Google Scholar]
  54. AmnuaikitT. LimsuwanT. KhongkowP. BoonmeP. Vesicular carriers containing phenylethyl resorcinol for topical delivery system; liposomes, transfersomes and invasomes.Asian J Pharmaceut Sci201813547248410.1016/j.ajps.2018.02.004 32104421
     [Google Scholar]
  55. BabaieS. CharkhpourM. KouhsoltaniM. HamishehkarH. Paiva-SantosA.C. Nano‐invasomes for simultaneous topical delivery of buprenorphine and bupivacaine for dermal analgesia.Exp. Dermatol.20233291459146710.1111/exd.14850 37283479
     [Google Scholar]
  56. DsouzaL. ChaudhariP. BrahmamB. LewisS.A. Derma roller mediated transdermal delivery of tizanidine invasomes for the management of skeletal muscle spasms.Eur. J. Pharm. Sci.202116510592010.1016/j.ejps.2021.105920 34192586
     [Google Scholar]
  57. El-NabarawiM.A. ShammaR.N. FaroukF. NasrallaS.M. Dapsone-loaded invasomes as a potential treatment of acne: Preparation, characterization, and in vivo skin deposition assay.AAPS PharmSciTech20181952174218410.1208/s12249‑018‑1025‑0 29725903
     [Google Scholar]
  58. JainS. TripathiS. TripathiP.K. Antiarthritic potential of berberine loaded invasomal gel.Phytomedicine Plus20222410037310.1016/j.phyplu.2022.100373
     [Google Scholar]
  59. KumariS. AlsaidanO.A. MohantyD. Development of soft luliconazole invasomes gel for effective transdermal delivery: Optimization to in-vivo antifungal activity.Gels20239862610.3390/gels9080626 37623081
     [Google Scholar]
  60. JainS. TripathiS. TripathiP.K. Invasomes: Potential vesicular systems for transdermal delivery of drug molecules.J. Drug Deliv. Sci. Technol.20216110216610.1016/j.jddst.2020.102166
     [Google Scholar]
  61. AkbarzadehA. Rezaei-SadabadyR. DavaranS. Liposome: Classification, preparation, and applications.Nanoscale Res. Lett.20138110210.1186/1556‑276X‑8‑102 23432972
     [Google Scholar]
  62. JiaJ.X. PengS.L. KalisaN.Y. A liposomal carbohydrate vaccine, adjuvanted with an NKT cell agonist, induces rapid and enhanced immune responses and antibody class switching.J. Nanobiotechnology202321117510.1186/s12951‑023‑01927‑x 37264420
     [Google Scholar]
  63. OritaY. ShimanukiS. OkadaS. Acoustic-responsive carbon dioxide-loaded liposomes for efficient drug release.Ultrason. Sonochem.20239410632610.1016/j.ultsonch.2023.106326 36796146
     [Google Scholar]
  64. RajabiM. MousaS.A. Lipid nanoparticles and their application in nanomedicine.Curr. Pharm. Biotechnol.201617866267210.2174/1389201017666160415155457 27087491
     [Google Scholar]
  65. RaniN.N.I.M. ChenX.Y. Al-ZubaidiZ.M. Surface-engineered liposomes for dual-drug delivery targeting strategy against methicillin-resistant Staphylococcus aureus (MRSA).Asian J Pharmaceut Sci202217110211910.1016/j.ajps.2021.11.004 35261647
     [Google Scholar]
  66. SalehiB. MishraA.P. NigamM. Multivesicular liposome (Depofoam) in human diseases.Iran. J. Pharm. Res.2020192921 33224207
     [Google Scholar]
  67. WangY. YeA. HouY. Microcapsule delivery systems of functional ingredients in infant formulae: Research progress, technology, and feasible application of liposomes.Trends Food Sci. Technol.2022119364410.1016/j.tifs.2021.11.016
     [Google Scholar]
  68. XiL. LinZ. QiuF. Enhanced uptake and anti-maturation effect of celastrol-loaded mannosylated liposomes on dendritic cells for psoriasis treatment.Acta Pharm. Sin. B202212133935210.1016/j.apsb.2021.07.019 35127390
     [Google Scholar]
  69. YuwandaA. SuriniS. HarahapY. JufriM. Study of valproic acid liposomes for delivery into the brain through an intranasal route.Heliyon202283e0903010.1016/j.heliyon.2022.e09030 35284670
     [Google Scholar]
  70. IbrahimS. TagamiT. KishiT. OzekiT. Curcumin marinosomes as promising nano-drug delivery system for lung cancer.Int. J. Pharm.20185401-2404910.1016/j.ijpharm.2018.01.051 29408473
     [Google Scholar]
  71. Javed AnsariM. AldawsariM.F. ZafarA. In vitro release and cytotoxicity study of encapsulated sulfasalazine within LTSP micellar/liposomal and TSP micellar/niosomal nano-formulations.Alex. Eng. J.202261129749975610.1016/j.aej.2022.02.019
     [Google Scholar]
  72. AsaithambiK. MuthukumarJ. ChandrasekaranR. EkambaramN. RoopanM. Synthesis and characterization of turmeric oil loaded non-ionic surfactant vesicles (niosomes) and its enhanced larvicidal activity against mosquito vectors.Biocatal. Agric. Biotechnol.20202910173710.1016/j.bcab.2020.101737
     [Google Scholar]
  73. KhanD.H. BashirS. KhanM.I. FigueiredoP. SantosH.A. PeltonenL. Formulation optimization and in vitro characterization of rifampicin and ceftriaxone dual drug loaded niosomes with high energy probe sonication technique.J. Drug Deliv. Sci. Technol.20205810176310.1016/j.jddst.2020.101763
     [Google Scholar]
  74. ObeidM.A. HaifawiS. KhadraI. The impact of solvent selection on the characteristics of niosome nanoparticles prepared by microfluidic mixing.Int. J. Pharm. X2023510016810.1016/j.ijpx.2023.100168 36852395
     [Google Scholar]
  75. Piri-GharaghieT. GhajariG. HassanpoorM. Investigation of antibacterial and anticancer effects of novel niosomal formulated Persian Gulf Sea cucumber extracts.Heliyon202393e1414910.1016/j.heliyon.2023.e14149 36938478
     [Google Scholar]
  76. RajizadehM.A. NematollahiM.H. JafariE. Niosome nanocarrier enhances the ameliorating effects of myrtenol in the lungs of rats with experimental asthma.OpenNano20231110012910.1016/j.onano.2023.100129
     [Google Scholar]
  77. YasamV.R. JakkiS.L. NatarajanJ. KuppusamyG. A review on novel vesicular drug delivery.Proniosomes. Drug Deliv201421424324910.3109/10717544.2013.841783 24128089
     [Google Scholar]
  78. FatimaI. RasulA. ShahS. Novasomes as nano-vesicular carriers to enhance topical delivery of fluconazole: A new approach to treat fungal infections.Molecules2022279293610.3390/molecules27092936 35566287
     [Google Scholar]
  79. MosallamS. RagaieM.H. MoftahN.H. ElshafeeyA.H. AbdelbaryA.A. Use of novasomes as a vesicular carrier for improving the topical delivery of terconazole: In vitro characterization, in vivo assessment and exploratory clinical experimentation.Int. J. Nanomedicine20211611913210.2147/IJN.S287383 33447031
     [Google Scholar]
  80. SinghA. MalviyaR. SharmaP.K. Novasome-a breakthrough in pharmaceutical technology a review article.Adv. Biol. Res. (Faisalabad)201154184189
     [Google Scholar]
  81. AbdelbariM.A. ElshafeeyA.H. AbdelbaryA.A. MosallamS. Implementing nanovesicles for boosting the skin permeation of non-steroidal anti-inflammatory drugs.AAPS PharmSciTech202324719510.1208/s12249‑023‑02649‑x 37770750
     [Google Scholar]
  82. DawoudM.H.S. ZaafanM.A. SalehS.S. MannaaI.M. SweedN.M. Response surface optimization of a cardioprotective compound through pharmacosomal drug delivery system: In vivo bioavailability and cardioprotective activity potential.Drug Deliv. Transl. Res.20231392315233910.1007/s13346‑023‑01315‑w 37017879
     [Google Scholar]
  83. KaurG. NegiK. KumarK. TeotiaD. Development and evaluation of Pharmacosome formulations of Mefenamic acid.GSC Biol Pharma Sci202116322923410.30574/gscbps.2021.16.3.0286
     [Google Scholar]
  84. SemaltyA. SemaltyM. RawatB.S. SinghD. RawatM.M. Development and evaluation of pharmacosomes of aceclofenac.Indian J. Pharm. Sci.201072557658110.4103/0250‑474X.78523 21694988
     [Google Scholar]
  85. SemaltyA. SemaltyM. SinghD. RawatM. Development and physicochemical evaluation of pharmacosomes of diclofenac.Acta Pharm.200959333534410.2478/v10007‑009‑0023‑x 19819829
     [Google Scholar]
  86. SinghS. ShuklaR. Nanovesicular-mediated intranasal drug therapy for neurodegenerative disease.AAPS PharmSciTech202324717910.1208/s12249‑023‑02625‑5 37658972
     [Google Scholar]
  87. XueF. LinX. CaiZ. LiuX. MaY. WuM. Doxifluridine-based pharmacosomes delivering miR-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma.Colloids Surf. B Biointerfaces202119711136710.1016/j.colsurfb.2020.111367 33007506
     [Google Scholar]
  88. AdikiS.K. SangeethaS. KamireddyS. KatakamP. ObilineniI. Phytosomes: A novel phytoconstituent delivery approach to improve the efficacy of obesity treatment.Curr. Nutr. Food Sci.202319322923710.2174/1573401318666220901125859
     [Google Scholar]
  89. ChivteP.S. PardhiV.S. JoshiV.A. RaniA. A review on therapeutic applications of phytosomes.J. Drug Deliv. Ther.201775172110.22270/jddt.v7i5.1513
     [Google Scholar]
  90. HumanC. AucampM. de BeerD. van der RijstM. JoubertE. Food‐grade phytosome vesicles for nanoencapsulation of labile C ‐glucosylated xanthones and dihydrochalcones present in a plant extract matrix—Effect of process conditions and stability assessment.Food Sci. Nutr.202311128093811110.1002/fsn3.3730 38107118
     [Google Scholar]
  91. MahmoodT.H. Al-SamydaiA. SulaibiM.A. Development of pegylated nano‐phytosome formulation with oleuropein and rutin to compare anti‐colonic cancer activity with Olea europaea leaves extract.Chem. Biodivers.2023208e20230053410.1002/cbdv.202300534 37498138
     [Google Scholar]
  92. PadmakumariP. Mohan MandaR. Design, formulation, biopharmaceutical evaluation and in-vitro screening of boldine phytosomes for breast cancer therapy.Mater. Today Proc.2023202312410.1016/j.matpr.2023.08.123
     [Google Scholar]
  93. PeanparkdeeM. YooyingR. Enhancement of solubility, thermal stability and bioaccessibility of vitexin using phosphatidylcholine-based phytosome.NFS J.202331283810.1016/j.nfs.2023.03.001
     [Google Scholar]
  94. SafariZ. BagherniyaM. KhoramZ. The effect of curcumin on anthropometric indices, blood pressure, lipid profiles, fasting blood glucose, liver enzymes, fibrosis, and steatosis in non-alcoholic fatty livers.Front. Nutr.202310116395010.3389/fnut.2023.1163950 37275651
     [Google Scholar]
  95. TalaatS.M. ElnaggarY.S.R. GowayedM.A. El-GanainyS.O. AllamM. AbdallahO.Y. Novel PEGylated cholephytosomes for targeting fisetin to breast cancer: In vitro appraisal and in vivo antitumoral studies.Drug Deliv. Transl. Res.2024142433454 37644299
     [Google Scholar]
  96. AibaniN. NesbittH. MarinoN. Electroneutral polymersomes for combined cancer chemotherapy.Acta Biomater.20188032734010.1016/j.actbio.2018.09.005 30201433
     [Google Scholar]
  97. AlibolandiM. AbnousK. SadeghiF. HosseinkhaniH. RamezaniM. HadizadehF. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.Int. J. Pharm.20165001-216217810.1016/j.ijpharm.2016.01.040 26802496
     [Google Scholar]
  98. AlibolandiM. RamezaniM. AbnousK. SadeghiF. HadizadehF. Comparative evaluation of polymersome versus micelle structures as vehicles for the controlled release of drugs.J. Nanopart. Res.20151727610.1007/s11051‑015‑2878‑8
     [Google Scholar]
  99. GeilichB.M. GelfatI. SridharS. van de VenA.L. WebsterT.J. Superparamagnetic iron oxide-encapsulating polymersome nanocarriers for biofilm eradication.Biomaterials2017119788510.1016/j.biomaterials.2016.12.011 28011336
     [Google Scholar]
  100. JainJ.P. JatanaM. ChakrabartiA. KumarN. Amphotericin-B-loaded polymersomes formulation (PAMBO) based on (PEG)3-PLA copolymers: An in vivo evaluation in a murine model.Mol. Pharm.20118120421210.1021/mp100267k 21138276
     [Google Scholar]
  101. JainJ.P. KumarN. Development of amphotericin B loaded polymersomes based on (PEG)3-PLA co-polymers: Factors affecting size and in vitro evaluation.Eur. J. Pharm. Sci.201040545646510.1016/j.ejps.2010.05.005 20580669
     [Google Scholar]
  102. NomaniA. NosratiH. ManjiliH. KhesalpourL. DanafarH. Preparation and characterization of copolymeric polymersomes for protein delivery.Drug Res. (Stuttg.)201767845846510.1055/s‑0043‑106051 28561240
     [Google Scholar]
  103. ZavvarT. BabaeiM. AbnousK. Synthesis of multimodal polymersomes for targeted drug delivery and MR/fluorescence imaging in metastatic breast cancer model.Int. J. Pharm.202057811909110.1016/j.ijpharm.2020.119091 32007591
     [Google Scholar]
  104. SharmaA.K. PrasherP. AljabaliA.A. Emerging era of “somes”: Polymersomes as versatile drug delivery carrier for cancer diagnostics and therapy.Drug Deliv. Transl. Res.20201051171119010.1007/s13346‑020‑00789‑2 32504410
     [Google Scholar]
  105. KhudairN. AgouniA. ElrayessM.A. NajlahM. YounesH.M. ElhissiA. Letrozole-loaded nonionic surfactant vesicles prepared via a slurry-based proniosome technology: Formulation development and characterization.J. Drug Deliv. Sci. Technol.20205810172110.1016/j.jddst.2020.101721
     [Google Scholar]
  106. RadhaG.V. RaniT.S. SarvaniB. A review on proniosomal drug delivery system for targeted drug action.J. Basic Clin. Pharm.201342424810.4103/0976‑0105.113609 24808669
     [Google Scholar]
  107. RamkanthS. ChettyC.M. SudhakarY. ThiruvengadarajanV.S. AnithaP. GopinathC. Development, characterization & in vivo evaluation of proniosomal based transdermal delivery system of Atenolol.Future J Pharmaceut Sci201841808710.1016/j.fjps.2017.10.003
     [Google Scholar]
  108. LopezC David-BriandE MériadecC BourgauxC PérezJ ArtznerF Milk sphingosomes as lipid carriers for tocopherols in aqueous foods: Thermotropic phase behaviour and morphology.Food Res Int2022162Pt B11211510.1016/j.foodres.2022.112115 36461349
     [Google Scholar]
  109. LopezC MériadecC David-BriandE Loading of lutein in egg-sphingomyelin vesicles as lipid carriers: Thermotropic phase behaviour, structure of sphingosome membranes and lutein crystals.Food Res Int2020138Pt A10977010.1016/j.foodres.2020.109770 33292950
     [Google Scholar]
  110. ChenY. AngelovaA. AngelovB. Sterically stabilized spongosomes for multidrug delivery of anticancer nanomedicines.J. Mater. Chem. B Mater. Biol. Med.20153397734774410.1039/C5TB01193K 32264582
     [Google Scholar]
  111. RakotoarisoaM. AngelovB. GaramusV.M. AngelovaA. Curcumin-and fish oil-loaded spongosome and cubosome nanoparticles with neuroprotective potential against H2O2-induced oxidative stress in differentiated human SH-SY5Y cells.ACS Omega2019423061307310.1021/acsomega.8b03101
     [Google Scholar]
  112. YoonB.K. LimZ.Y. JeonW.Y. ChoN.J. KimJ.H. JackmanJ.A. Medicinal activities and nanomedicine delivery strategies for Brucea javanica oil and its molecular components.Molecules20202522541410.3390/molecules25225414 33228061
     [Google Scholar]
  113. ZouA. LiY. ChenY. Self-assembled stable sponge-type nanocarries for Brucea javanica oil delivery.Colloids Surf. B Biointerfaces201715331031910.1016/j.colsurfb.2017.02.031 28285062
     [Google Scholar]
  114. El-NaggarM.M. El-NabarawiM.A. TeaimaM.H. Integration of terpesomes loaded Levocetrizine dihydrochloride gel as a repurposed cure for Methicillin-Resistant Staphylococcus aureus (MRSA)-Induced skin infection; D-optimal optimization, ex-vivo, in-silico, and in-vivo studies.Int. J. Pharm.202363312262110.1016/j.ijpharm.2023.122621 36693486
     [Google Scholar]
  115. TawfikM.A. EltaweelM.M. FatouhA.M. Shamsel-DinH.A. IbrahimA.B. Brain targeting of zolmitriptan via transdermal terpesomes: Statistical optimization and in vivo biodistribution study by 99mTc radiolabeling technique.Drug Deliv. Transl. Res.202313123059307610.1007/s13346‑023‑01373‑0 37273147
     [Google Scholar]
  116. MosallamS. AlbashR. AbdelbariM.A. Advanced vesicular systems for antifungal drug delivery.AAPS PharmSciTech202223620610.1208/s12249‑022‑02357‑y 35896903
     [Google Scholar]
  117. CristianoM.C. FroiioF. MancusoA. Oleuropein-laded ufasomes improve the nutraceutical efficacy.Nanomaterials (Basel)202111110510.3390/nano11010105 33406805
     [Google Scholar]
  118. SalamaA.H. AburahmaM.H. Ufasomes nano-vesicles-based lyophilized platforms for intranasal delivery of cinnarizine: Preparation, optimization, ex-vivo histopathological safety assessment and mucosal confocal imaging.Pharm. Dev. Technol.2016216706715 25996631
     [Google Scholar]
  119. DaubenbergerC.A. PluschkeG. ZurbriggenR. WesterfeldN. Development of influenza virosome-based synthetic malaria vaccines.Expert Opin. Drug Discov.20083441542310.1517/17460441.3.4.415 23489097
     [Google Scholar]
  120. SinghN. GautamS.P. KumariN. KaurR. KaurM. Virosomes as novel drug delivery system: An overview.PharmaTutor2017594755
     [Google Scholar]
  121. AlmeidaJ. EdwardsD.C. BrandC. HeathT. Formation of virosomes from influenza subunits and liposomes.Lancet1975306794189990110.1016/S0140‑6736(75)92130‑3 53375
     [Google Scholar]
  122. TaoT. RehmanS. XuS. A biomimetic camouflaged metal organic framework for enhanced siRNA delivery in the tumor environment.J. Mater. Chem. B Mater. Biol. Med.202412174080409610.1039/D3TB02827E
     [Google Scholar]
  123. KumarB. RanaV.S. SinghalM. SethiyaN.J. Baicalein-loaded aquasomes and preparation method.IN Patent 2022110375922022
  124. SrivastavaV. NairV.S. BhawanaV. Enhanced permeation and pharmaceutical composition of carbonic anhydrase inhibitor loaded ultra-deformable bile salts stabilized vesicular system.IN Patent 2023410043052023
  125. GalgatteU.C. KolsureS.R. ChaudhariP.D. Cubosomal nasal spray of Topiramate.IN Patent 2023210111712023
  126. KumarS.B. MarbaniangR.W. RaghavendraN.M. Ethosome hydrogel hybrid technology (EHT) for topical drug delivery applicationIN Patent 2022410008772022
  127. JoyceJ. TaylorD. TaylorC. Exosomeal tau as a biomarker for brain disorders.US Patent 202101091152021
  128. WangM. SaravanakumarK. Fresh cut paprika using green synthetic silver nanoparticles-polyvinyl pyrrolidone-based glycerosomes and preparation method thereof.KR Patent 10202100223382021
  129. TiwariA. JoshiG. TiwariV. Formulation, characterization and evaluation of Andrographis paniculata herbosomes for improved permeability.IN Patent 2022110048362022
  130. SriramA. IthapeA. PandaB. SinghP.K. SinghS.B. GoduguC. Nano-hyalurosomal gel of Tofacitinib citrate and Boric acid for the management of rheumatoid arthritis.IN Patent 2023410216212023
  131. SailajaA.K. Formulation of invasomal drug delivery system for mefenamic acid.IN Patent 2023440151312023
  132. HuangA. SaytaK. Liposome/Doxorubicin composition and method.WO Patent 1988/0091681988
  133. MiyaniV.P. ManishKumar P.P. ManeshT.C. A novel niosome formulation of olopatadine hydrochloride.IN Patent 2023210174572023
  134. HoglianD. DaiY. GSH concentration responsive pharmacosome for treating hyperthyroidism and preparation method.CN Patent 1119391182020
  135. SeemaS. KumrS. JalwalP. Swertiamarin-loaded phytosome preparation, identification, and assessment.IN Patent 2023110056312023
  136. BhattacharyaS. SindaneD. A method for preparation of 5-Fluorouracil loaded unsaturated fatty acid vesicles or liposomes (ufasome) and a combinationIN Patent 2022210053052022
  137. AdriaansenJ. DoroF. . Formulations for virosome.US Patent 202003605102020
  138. Formulation and clinical evaluation of ethosomal and liposomal preparations of anthralin in psoriasis. ClinicalTrials.gov [Internet]. Identifier NCT03348462.Available from: https://clinicaltrials.gov/ct2/show/NCT03348462. Accessed: 20 Apr 2024.
  139. Retinyl palmitate loaded ethosomes in acne vulgaris. ClinicalTrials.gov [Internet]. Identifier NCT04080869.Available from: https://clinicaltrials.gov/ct2/show/NCT04080869. Accessed: 20 Apr 2024.
  140. A pilot clinical study on inhalation of mesenchymal stem cells exosomes treating severe novel coronavirus pneumonia. ClinicalTrials.gov [Internet]. Identifier NCT04276987.Available from: https://clinicaltrials.gov/ct2/show/NCT04276987. Accessed: 20 Apr 2024.
  141. Trial of a vaccination with tumour antigen loaded dendritic cell derived exosome. ClinicalTrials.gov [Internet]. Identifier NCT01159288.Available from: https://clinicaltrials.gov/ct2/show/NCT01159288. Accessed: 20 Apr 2024.
  142. A pilot bioequivalence study between Amphotericin B liposome for injection and AmBisome®. ClinicalTrials.gov [Internet]. Identifier NCT04993222.Available from: https://clinicaltrials.gov/ct2/show/NCT04993222. Accessed: 20 Apr 2024.
  143. In-vivo investigation of Novel nano nanovesicles of salbutamol sulphate. ClinicalTrials.gov [Internet]. Identifier NCT03059017.Available from: https://clinicaltrials.gov/ct2/show/NCT03059017. Accessed: 20 Apr 2024.
  144. Artichoke and Bergamot phytosome. ClinicalTrials.gov [Internet]. Identifier NCT04697121.Available from: https://clinicaltrials.gov/ct2/show/NCT04697121. Accessed: 20 Apr 2024.
  145. Phase Ib trial of two virosome formulated malaria vaccine components (PEV 301, PEV 302) in Tanzania (PMAL03). ClinicalTrials.gov [Internet]. Identifier NCT00513669.Available from: https://clinicaltrials.gov/ct2/show/NCT00513669. Accessed: 20 Apr 2024.
/content/journals/cnm/10.2174/0124054615325001240809093127
Loading
Emerging Trends, Multifaceted Implications, Patent Information and Clinical Trial Status of Nanovesicular Carriers: A Concurrent Review
Curr. Nanomater. 11, 1 (2026); https://doi.org/10.2174/0124054615325001240809093127
/content/journals/cnm/10.2174/0124054615325001240809093127
/content/journals/cnm/10.2174/0124054615325001240809093127
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Bingham bodies; chemotherapy; Nanovesicles; physicochemical characteristics; specific drug targeting; vesicular

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test